וויז פארמה ממנה את מרק סיצ'קרק ליו"ר הדירקטוריון, נועם דננברג מונה למנכ"ל

Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, is pleased to announce that Mr. Mark Sieczkarek has been appointed Chairman of Wize Pharma's Board of Directors, replacing Mr. Noam Danenberg, who will become the Company's Chief Executive Officer, effective April 23, 2019.

Mr. Sieczkarek has more than 39 years of leadership experience in the medical industry, including from 2006 to 2014 as CEO and Chairman of the Board of Solta Medical. Prior to its acquisition by Valeant Pharmaceuticals International, and from 2003 to 2011 as President and CEO of Conceptus, prior to its acquisition by Bayer Pharmaceuticals. From 1995 to 2003, Mr. Sieczkarek held multiple roles of increasing responsibility at Bausch & Lomb ("B&L"), ultimately becoming Senior Vice President and President of the Americas region, where he was responsible for the commercial operation of all B&L businesses in the United States, Canada, and Latin America. He also served as President of the European region. Mr. Sieczkarek also held senior executive level positions with KOS Pharmaceuticals, several Bristol Myers-Squibb subsidiaries, and Sanofi Diagnostics Pasteur. Mr. Sieczkarek earned an MBA in Finance from Canisius College in Buffalo, New York and a BS in Accounting from the State University of New York at Buffalo. He also was past Chairman and CEO of NovaBay Pharma and continues to serve there as a Director.

"We are fortunate to have Mark Sieczkarek, with his experience and expertise, join Wize Pharma as Chairman of the Board. I don't believe there is a better-suited person for this role and Mark's taking over as Chairman could not come at a more auspicious time for the Company and our shareholders. Mark's four decades of industry experience in combination with strong investor relationships will be invaluable as we seek greater visibility in the U.S.," said Noam Danenberg, Wize Pharma's Chief Executive Officer. "We look forward to his guidance as we advance our current clinical programs and expand our pipeline through opportunistic acquisitions and/or licensing of new ophthalmic products. Personally, I greatly look forward to my new role as Chief Executive Officer."

"Wize Pharma represents an exciting commercial and business opportunity, and I am extremely pleased to join the Company as Chairman," commented Mr. Sieczkarek. "Eye health has long been an area of my professional focus, and I look forward to contributing to the development of this growing company as we strengthen our position in the U.S. and certain global markets."

About Wize Pharma, Inc.
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's syndrome (Sjögren's).

LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and Sjögren's and in the Netherlands for the treatment of DES and Sjögren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A. Wize has finished a Phase II trial of LO2A for patients with CCH and is currently conducting a Phase IV study for LO2A for DES in patients with Sjögren's.